Skip to main content
OpenTrials
Completed

NCT Number: NCT02079090

Ketofol Versus Fentofol for Procedural Sedation in the Pediatric Emergency Department

Sedation and pain medication is required when bone fractures need to be fixed in the emergency department (ED). Many drugs have been used safely as single agents or in combination for the sedation of children. These drugs include Propofol, Ketamine and Fentanyl. However each of these medications has side effects and drawbacks. The combination of Propofol and Fentanyl (Fentofol) has never been compared directly with the combination of Propofol and Ketamine (Ketofol) for painful procedures in the ED, and the goal of this study is to determine which combination works better. The primary outcome of this study is to determine which drug combination has a shorter time from onset of sedation to full recovery. The investigators hypothesize that Fentofol will have shorter sedation to recovery times.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Emergency Department Procedural Sedation Disease Attributes Emergencies Fracture Reduction Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

3 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University of British Columbia: BC Children's Hospital

Vancouver, British Columbia, V6H 3V4, Canada

About this study

Purpose: The purpose of this study is to compare the duration of procedural sedation and analgesia (PSA) from time of medication delivery to recovery for children in the ED provided by Fentofol and Ketofol.

Hypothesis: The hypothesis is that Fentofol will have a shorter duration of sedation time as compared to Ketofol.

Justification: PSA for children is a common occurrence in the ED and has been performed using Ketamine or Propofol. Propofol offers several advantages over Ketamine, including shorter recovery times, and low rates of nausea and vomiting. Propofol is a potent sedative-hypnotic that does not provide analgesia, hence another agent is commonly used in combination for painful procedures. Propofol has been used in combination with Ketamine (Ketofol) and with Fentanyl (Fentofol) to improve the quality of sedation for painful procedures such as fracture reduction. Ketofol has been shown in a double blind randomized controlled trial to be at least equivalent, or even superior to Ketamine in children who are undergoing PSA, with shorter duration of sedation, increased provider and patient satisfaction, and reduced frequency of nausea/vomiting events. A combination of 1 to 2 microgram/kg Fentanyl and 1 mg/kg Propofol has been shown to substantially reduce recovery time as compared to 0.05 mg/kg Midazolam and 1 to 2 mg/kg Ketamine, and provided adequate levels of analgesia during PSA. As a result, both Ketofol and Fentofol are considered standard treatments for PSA in the ED. However, there is currently no pediatric literature available comparing Ketofol and Fentofol for PSA in the ED setting and the results of this study will potentially identify which of the two sedation agents is superior.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children 3-17 years of age
  • Presenting to the ED for assessment of a long bone fracture
  • Require PSA for closed reduction of the fracture
  • American Society of Anesthesia Grade I or II

Exclusion criteria

  • Families not providing informed consent (or assent where appropriate)
  • Families unable to communicate in English
  • Children sustained life- or limb-threatening injuries
  • Children involved in a multi-system trauma
  • Children with a pathological fractures
  • Children with a contraindication to using Propofol, Ketamine or Fentanyl:

Allergy or previous adverse reaction to study drugs Psychosis/schizophrenia Active upper respiratory tract infection or asthma, or chronic respiratory illnesses Coronary artery disease, congestive heart failure, hypertension, or chronic cardiac disease Chronic renal disease Increased intracranial pressure Porphyria or thyroid disorder

  • Severe developmental delay or autism

Treatment and study plan

Ketofol

Drug

0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).

Fentofol

Drug

1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)

Primary outcomes

  1. Duration of Sedation

    Time frame: Less than 30 minutes

    Duration of sedation is measured from time of administration of Propofol (time 0) to recovery being achieved.

Secondary outcomes

  1. Recovery Time

    Time frame: Less than 30 minutes

    Measured from time of last dose of study drug administered to recovery

  2. Additional analgesia or sedation medications

    Time frame: Less than 30 minutes

    Use of additional analgesic agents and sedation medications to complete PSA

  3. Efficacy of sedation for completion of procedure

    Time frame: Less than 30 minutes

    A sedation is considered efficacious if: the patient does not have unpleasant recall of the procedure, the patient did not experience sedation-related adverse events resulting in abandonment of the procedure/permanent complication/unplanned admission to the hospital or ED, and the patient did not actively resist the procedure or require restraints.

  4. Satisfaction with sedation

    Time frame: Less than 60 minutes

    Satisfaction scores will be completed by the physician performing the sedation, the physician performing the procedure, the nurse performing the sedation and by the patient in the ED. This outcome will by measured using a 5-point Likert scale, except in children between ages 6 and 9, where a 5-point facial hedonic scale is used.

  5. Incidence of adverse events

    Time frame: From initiation of PSA until 48 to 72 hours post-ED discharge

    Adverse events, interventions and outcomes will be measured using the "Quebec Guidelines".

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Collaborators

  • Child and Family Research Institute

Registry information

Official study title

Ketofol Versus Fentofol for Procedural Sedation of Children 3 to 17 Years Old: a Double-Blind Randomized Controlled Trial

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Mar 5, 2014
Registry last updated
Oct 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.